NASDAQ •
Healthcare •
Biotechnology •
Quote as of 06/23/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization2,275.37 mln
Float60.37 mln
Earnings Date08/18/2026
Piotroski F-Score
4
/ 9
Borderline
1-Year Forecast
49.00
Transformational upside
Relative Strength
92
/ 100
Top performer
Debt / Equity
0.00
Debt-free
ROE
-30.16
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Mineralys Therapeutics is a U.S.-based drug development company focused on conditions caused by the body producing too much of the hormone aldosterone, which plays a key role in regulating blood pressure and kidney function. Its lead drug candidate, lorundrostat, is a pill designed to block the enzyme responsible for aldosterone production and is being studied as a potential treatment for high blood pressure, chronic kidney disease, and sleep apnea. Founded in 2019 and based in Radnor, Pennsylvania, the company operates under a name it adopted in 2020.
